Novartis Confident Cosentyx Can Keep Competition At Bay
Sales Expected To Grow Beyond $5bn
Executive Summary
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
You may also be interested in...
UCB Is RADIANT As Bimekizumab Beats Cosentyx For Psoriasis
The psoriasis market is crowded and fiercely competitive but the Belgian group's bimekizumab has bested Novartis's interleukin-17A behemoth Cosentyx in a head-to-head study. Whether UCB goes it alone or signs up a large partner with a large marketing budget remains to be seen.
Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis
Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.
Can UCB's Bimekizumab Go From Last To First In Psoriasis?
Although it is playing catching up on well-established rivals, especially Novartis's Cosentyx, the Belgian company believes that bimekizumab provides both a fast and durable response for psoriasis patients, driven by impressive PASI 100 rates.